Old Internet rumors never die. Is it true that tampons are dangerous due to asbestos, dioxin, and rayon? Tampon safety has improved but toxic shock and other possible risks remain. Here’s what you need to know.
Read More »Medical Care for Adults
The National Center for Health Research reviews important new research as soon as it is published. We cut through the hype regarding various medical treatments to let you know what is proven and what is unknown about the risks and benefits of various treatment options. We do not accept funding from the companies that make medical products, so you can trust that our information is based on science, and not biased by financial ties to the treatments we’re evaluating.
To find the information you need, please use our search box to search for exactly what you are looking for or browse through our various topics on the right. →
Some of these articles were written this year and others were not, however, if they are on our website it means the information is up-to-date. We always scrutinize new research and call the researchers to learn even more. Then we translate it into plain language that everyone can understand.
If you’re looking for more detailed information about cancer, please go to our Cancer Prevention and Treatment website.
If you don’t see what you are looking for on any health topic, please contact us and we will try to get the information you need within a few days.
Hormone Therapy and Menopause: Facts and Fiction
Hormone therapy for menopause has risks and benefits. Research results are nuanced, despite FDA Makary and RFK claims that it improves most women’s health. Both risks and benefits depend on the woman’s age and medical history and genetics, the type of hormones, and other factors .
Read More »The FDA removes long-standing warning from hormone-based menopause drugs
AP News, November 10, 2025: AP explains FDA decision to
delete most black box warnings for hormone therapy for menopause,
despite controversies about the risks. NCHR’s Diana Zuckerman
says FDA lost credibility for deleting such important warnings without
scientific review using FDA Advisory Committee.
Responses to Questions for the September 18, 2025, Energy & Commerce Health Committee Hearing Record
NCHR’s Diana Zuckerman responds to written questions from the September 18, 2025, Energy & Commerce Health Committee hearing, addressing breakthrough medical devices, access for rural and older patients, evidence standards for Medicare coverage, multi-cancer screening tests, and the impact of research and staffing cuts at FDA and NIH.
Read More »Some MAHA Supporters Say CNPV Could Lower FDA Standards
Inside Health Policy, October 23, 2025: Inside Health Policy quotes a MAHA meeting that criticized industry influence over FDA, the impact of user fees, the inappropriate reliance on surrogate endpoints for cancer screening and Alzheimer’s drugs. The Lever FDA report finding that most new drugs are approved on evidence inferior to the FDA’s legal standards. NCHR’s Diana Zuckerman is quoted criticizing the FDA’s new CNVP program that promises extremely fast priority reviews for high-impact drugs.
Read More »